BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37787935)

  • 1. Tumor-Targeted Delivery of IL-2 by Fusing with a pH Low Insertion Peptide for Antitumor Immunotherapy.
    Chu T; Cao B; Wang P; Li B; Ren J; Nie G; Wei J; Li S
    Bioconjug Chem; 2023 Oct; 34(10):1894-1901. PubMed ID: 37787935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-Targeted, Cytoplasmic Delivery of Large, Polar Molecules Using a pH-Low Insertion Peptide.
    Svoronos AA; Bahal R; Pereira MC; Barrera FN; Deacon JC; Bosenberg M; DiMaio D; Glazer PM; Engelman DM
    Mol Pharm; 2020 Feb; 17(2):461-471. PubMed ID: 31855437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. pHLIP(Var7)-P1AP suppresses tumor cell proliferation in MDA-MB-231 triple-negative breast cancer by targeting protease activated receptor 1.
    Yu M; Chen Y; Wang Z; Ding X
    Breast Cancer Res Treat; 2020 Apr; 180(2):379-384. PubMed ID: 32034579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and Evaluation of Radioiodine-Labeled pH (Low) Insertion Peptide Variant 7-Like Peptide as a Noninvasive Tumor Microenvironment Imaging Agent in a Mouse MDA-MB-231 Triple-Negative Breast Cancer Model.
    Wu F; Chen Y; Li D; Wang Z; Yu M
    Mol Imaging Biol; 2022 Aug; 24(4):570-579. PubMed ID: 35006491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ku80-Targeted pH-Sensitive Peptide-PNA Conjugates Are Tumor Selective and Sensitize Cancer Cells to Ionizing Radiation.
    Kaplan AR; Pham H; Liu Y; Oyaghire S; Bahal R; Engelman DM; Glazer PM
    Mol Cancer Res; 2020 Jun; 18(6):873-882. PubMed ID: 32098827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cancer cell proliferation and breast tumor targeting of pHLIP-monomethyl auristatin E conjugates.
    Burns KE; Robinson MK; Thévenin D
    Mol Pharm; 2015 Apr; 12(4):1250-8. PubMed ID: 25741818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pH-responsive pHLIP (pH low insertion peptide) nanoclusters of superparamagnetic iron oxide nanoparticles as a tumor-selective MRI contrast agent.
    Wei Y; Liao R; Mahmood AA; Xu H; Zhou Q
    Acta Biomater; 2017 Jun; 55():194-203. PubMed ID: 28363789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic modeling reveals parameters that govern tumor targeting and delivery by a pH-Low Insertion Peptide (pHLIP).
    Svoronos AA; Engelman DM
    Proc Natl Acad Sci U S A; 2021 Jan; 118(1):. PubMed ID: 33443162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fusion cytokine IL-2-GMCSF enhances anticancer immune responses through promoting cell-cell interactions.
    Wen Q; Xiong W; He J; Zhang S; Du X; Liu S; Wang J; Zhou M; Ma L
    J Transl Med; 2016 Feb; 14():41. PubMed ID: 26850448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pH low insertion peptide mediated cell division cycle-associated protein 1 -siRNA transportation for prostatic cancer therapy targeted to the tumor microenvironment.
    Zhao Z; Li C; Song B; Sun J; Fu X; Yang F; Wang H; Yan B
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1761-1767. PubMed ID: 30131247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Acidic Microenvironment Targeted Drug Delivery Based on pHLIP-Modified Mesoporous Organosilica Nanoparticles.
    Zhang Y; Dang M; Tian Y; Zhu Y; Liu W; Tian W; Su Y; Ni Q; Xu C; Lu N; Tao J; Li Y; Zhao S; Zhao Y; Yang Z; Sun L; Teng Z; Lu G
    ACS Appl Mater Interfaces; 2017 Sep; 9(36):30543-30552. PubMed ID: 28809111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis therapy antibody interleukin-2 fusion protein elicits prolonged and targeted antitumor effects in vivo.
    Ye L; Fan J; Shi X; Tao Q; Ye D; Xian Z; Zeng X; Li Y; Feng M; Ju D
    Appl Microbiol Biotechnol; 2014 May; 98(9):4053-61. PubMed ID: 24276620
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Zhang Y; Ji W; He L; Chen Y; Ding X; Sun Y; Hu S; Yang H; Huang W; Zhang Y; Liu F; Xia L
    Theranostics; 2018; 8(6):1690-1705. PubMed ID: 29556350
    [No Abstract]   [Full Text] [Related]  

  • 14. In Vivo Distribution and Therapeutic Efficacy of Radioiodine-Labeled pH-Low Insertion Peptide Variant 3 in a Mouse Model of Breast Cancer.
    Zhang M; Xi Y; Chen H; Hai W; Li B
    Mol Imaging; 2022; 2022():7456365. PubMed ID: 35903249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. pH-(low)-insertion-peptide (pHLIP) translocation of membrane impermeable phalloidin toxin inhibits cancer cell proliferation.
    An M; Wijesinghe D; Andreev OA; Reshetnyak YK; Engelman DM
    Proc Natl Acad Sci U S A; 2010 Nov; 107(47):20246-50. PubMed ID: 21048084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A smart tumor targeting peptide-drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7/Adr cells.
    Song Q; Chuan X; Chen B; He B; Zhang H; Dai W; Wang X; Zhang Q
    Drug Deliv; 2016 Jun; 23(5):1734-46. PubMed ID: 25853477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabonomic Investigation of Biological Effects of a New Vessel Target Protein tTF-pHLIP in a Mouse Model.
    Ding L; Zhang C; Liu Z; Huang Q; Zhang Y; Li S; Nie G; Tang H; Wang Y
    J Proteome Res; 2020 Jan; 19(1):238-247. PubMed ID: 31603327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiproliferative effect of pHLIP-amanitin.
    Moshnikova A; Moshnikova V; Andreev OA; Reshetnyak YK
    Biochemistry; 2013 Feb; 52(7):1171-8. PubMed ID: 23360641
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.